Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To view the French language version of this newsreel, click here.
